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Background: In chronic kidney disease (CKD), the patients on a low-protein diet are considered to be at high risk of
protein-energy wasting. Furthermore, a low-protein diet conceivably results in reduced intake of various nutrients. The
purpose of this study was to evaluate the effects of a novel high-calorie, low-protein liquid formula containing
eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), lactulose, raffinose, and indigestible dextrin on CKD patients.
Methods: A randomized controlled trial was conducted on the Department of Nephrology at the Tokyo Medical
University Hospital, Tokyo, Japan. Forty-three CKD patients prescribed a protein-restricted diet were randomly assigned
to a supplement (SUP) or control (CTR) group. All patients received dietary counselling. Only the SUP group was given
one or two packs (125 or 250 mL) daily of high-calorie, low-protein liquid formula. The intervention period was
16 weeks. Outcome measures of the study were body weight; body mass index (BMI); dietary protein, energy, and salt
intake; estimated glomerular filtration rate (eGFR); serum levels of albumin, triglyceride and LDL-cholesterol; plasma
fatty acid composition; plasma indoxyl sulfate level; creatinine clearance (Ccr); and urine protein excretion.
Results: There were no differences in energy intake and protein intake between the two groups. Body weight, BMI,
plasma eicosapentaenoic acid (EPA), and EPA/arachidonic acid (AA) ratio at 16 weeks were significantly higher in the
SUP group than in the CTR group. At 16 weeks, the CTR group showed significant decline in eGFR and significant
increase in plasma indoxyl sulfate, whereas the SUP group showed no significant changes from baseline.
Conclusions: Supplementation of a novel liquid formula may be beneficial for the management in CKD patients on a
protein-restricted diet.
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In chronic kidney disease (CKD), a low-protein diet is
expected to prevent several clinical complications and
delay dialysis initiation [1]. However, it is somewhat dif-
ficult to maintain a diet with simultaneously sufficient
energy and restricted protein. Furthermore, CKD pa-
tients on a low-protein diet are considered to be at high
risk of protein-energy wasting for several reasons, one of* Correspondence: t-nakao@tokyo-med.ac.jp
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tients on a low-protein diet often take foods specially de-
veloped for CKD such as low-protein rice. In addition,
calorie supplement may be useful, and a non-protein
calorie supplement has been reported to reduce protein
intake and urine protein excretion and increase esti-
mated glomerular filtration rate (eGFR) [3].
A low-protein diet conceivably results in reduced
intake of various nutrients in addition to energy. The
intake of eicosapentaenoic acid (EPA) and docosahexae-
noic acid (DHA) mainly found in fish is also lowered [4].
EPA and DHA are known to have various physiological
effects such as lowering inflammation, triglyceride, andicle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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of n-3 fatty acids significantly reduces urine protein ex-
cretion [6]. Thus, EPA and DHA may have renoprotec-
tive effects.
Probiotics or prebiotics, such as lactulose, raffinose,
and indigestible dextrin, are considered to be another
beneficial nutrient for CKD patients. Prebiotics have
various beneficial effects on the intestinal environment
and metabolism, such as intestinal microflora and glu-
cose homeostasis [7]. Previous research suggested that
probiotics and prebiotics reduce p-cresyl sulfate and in-
doxyl sulfate, which are known as uremic toxins pro-
duced by intestinal bacteria [8]. Indoxyl sulfate is
considered to be nephrotoxic and promote CKD pro-
gression [9]. Therefore, improving intestinal microflora
and reducing uremic toxins by prebiotics may be a
therapeutic target for CKD patients. Currently, there is
an ongoing trial designed to test whether synbiotics that
combine both probiotics and prebiotics reduce uremic
toxins including indoxyl sulfate in CKD patients [10].
The purpose of this study was to clarify the usefulness
of a novel high-calorie, low-protein liquid formula con-
taining EPA, DHA, lactulose, raffinose, and indigestible
dextrin for energy supplementation, and to evaluate its
effects on eGFR, nutritional status, plasma lipid profile,
and plasma indoxyl sulfate as a representative uremic




The study was a prospective, randomized, open-label,
controlled clinical trial. This study was conducted at the
Tokyo Medical University Hospital in Tokyo, Japan,
from May 2010 to May 2012. The study protocol was
approved by the ethics committee at the Tokyo Medical
University and informed consent was obtained from all
participants.
Participants
All participants were recruited from the Department of
Nephrology at the Tokyo Medical University Hospital.
The inclusion criteria were CKD stage 4 or 5 (eGFR
<30 mL/min/1.73 m2), prescribed a protein-restricted
diet of under 0.8 g protein per kilogram ideal body
weight per day, and 40 to 85 years of age. The exclusion
criteria were presence of critical liver diseases, malignant
diseases, or infectious diseases; food allergies to milk,
soybean, or fish; undergoing hemodialysis or planning
for hemodialysis initiation; habitual intake of supplement
containing prebiotics; participation in another clinical
study; assessed by the principal investigator to be unsuit-
able to participate in the trial or have difficulties to
complete the trial. The participants were randomlyassigned to a supplement (SUP) or a control (CTR) group.
Randomization was performed using the permuted block
method and stratified according to compliance to energy
intake and protein intake.
Dietary intervention
All participants received dietary counselling in addition
to medical treatment. If the participants had already re-
ceived carbon adsorbent (Kremezin® (Kureha Corpor-
ation, Tokyo, Japan)), probiotics, or ethyl icosapentate
(Epadel™ (Mochida Pharmaceutical Co., Ltd., Tokyo,
Japan)) before the study, they continued to receive the
same agent during the study. Participants in the SUP
group took one or two packs of the nutritional formula
Renagy bit™ (Morinaga Milk Industry Co., Ltd., Tokyo,
Japan) per day for 16 weeks. One pack of formula
(125 mL) provides 150 kcal (0.9 g protein, 31.2 g carbo-
hydrate, 4.2 g fat). The formula contains low sodium,
potassium, and phosphorus (45, 0–10, and 5–15 mg per
pack, respectively). Each pack contains 90 mg EPA,
40 mg DHA, and 4 g dietary fiber mainly consisting of
indigestible dextrin, 1 g lactulose, 1 g raffinose, 25 mg L-
carnitine, and also some trace minerals and vitamins.
Participants in the CTR group did not take the nutri-
tional formula. Dietary energy and protein prescriptions
were expressed as per kilogram ideal body weight (IBW),
defined as the weight for body mass index (BMI) of
22 kg/m2. Energy prescription was 30 kcal/kg IBW/day
and adjusted by body weight transition. Protein prescrip-
tion was set at a goal of 0.6–0.8 g/kg IBW/day. The SUP
group recorded their intake of the nutritional formula
on their designated chart every day throughout this
study. Compliance (%) for nutritional formula intake was
calculated from the number of packs determined by pa-
tient’s record and dietary interview.
Assessments and parameters
Body weight measurement, blood sampling, and 24-h
urine collection were conducted at 0, 8, and 16 weeks.
Plasma fatty acid composition and body composition
were measured at 0 and 16 weeks. Outcome measures of
the study were body weight, BMI, protein intake, energy
intake, salt intake, eGFR, serum albumin, serum trigly-
ceride, serum LDL-cholesterol, plasma fatty acid com-
position, plasma indoxyl sulfate, creatinine clearance
(Ccr), and urine protein excretion. Serum total protein,
prealbumin, total cholesterol, HDL cholesterol, creatin-
ine, C-reactive protein, and blood urea nitrogen (BUN)
were also measured. The eGFR was calculated by the
three-variable Japanese equation formerly reported [11].
Energy intake was estimated from the dietary interview
and dietary records for four or more days at each point
using the standard tables of food composition in Japan.
Protein intake was calculated by the Maroni formula
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culated from urine sodium excretion. Ccr was calculated
from serum creatinine, urine creatinine, and urine volume.
Energy intake and protein intake were expressed as per
IBW. Body composition was measured by InBody 2.0
(Biospace Co., Ltd., Seoul, Korea). Plasma fatty acid com-
position was measured by gas chromatography. Plasma in-
doxyl sulfate was measured by high-performance liquid
chromatography.
Statistical analysis
Participants with low nutritional formula compliance of
lower than 80 % were excluded from the analysis. Numer-
ical variables were expressed as mean ± standard deviation
(SD). For the baseline characteristics, comparisons of nu-
merical data were performed using Student’s t test and
comparisons of categorical data were performed using
Fisher’s exact test. Analysis of covariance was used to
evaluate the intervention effect in numerical variables with
the baseline value as a covariate. The changes from the
baseline were evaluated using paired Student’s t test. Loga-
rithmic normalized values of indoxyl sulfate concentra-
tions were used [13]. Differences with P < 0.05 (two-sided)
were considered statistically significant. All calculations




Flow diagram of participants is shown in Fig. 1. Of
61 patients recruited, 43 were randomly assigned to
the SUP group (21 patients) or the CTR group (22Fig. 1 Flow diagram of participantspatients). Two participants in the SUP group discon-
tinued the study before the nutritional formula intake
because of complication. One participant in the CTR
group dropped out after 6 weeks of the study (labora-
tory data until 8 weeks) because of dialysis initiation.
One participant in the SUP group was excluded from
analysis due to low compliance (below 80 %). Eventu-
ally, analyses were conducted in 18 participants in the
SUP group and 22 in the CTR group. Baseline char-
acteristics are shown in Table 1. With the exception
of BUN, no significant differences between two
groups were observed.Dietary intake
Energy intake and protein intake are shown in Table 2.
There were no significant differences between two
groups in energy intake and protein intake. There
were no significant changes from the baseline in en-
ergy intake (16-week intake versus baseline intake in
the SUP group, P = 0.07) and protein intake. Energy
intake from the nutritional formula in the SUP group
was 180 ± 60 kcal/day (1.2 ± 0.4 packs/day). Although
the rate of energy intake for a prescribed amount in
the SUP group increased from 93 ± 13 % at baseline
to 98 ± 14 % at 16 weeks, there was no significant dif-
ference (P = 0.09). The rate of energy intake for a pre-
scribed amount in the CTR group also increased
from 90 ± 15 % at baseline to 94 ± 14 % at 16 weeks,
also with no significant difference. Although the
formula contains indigestible dextrin, lactulose, and
raffinose, diarrhea was not observed in this study.
Table 1 Baseline characteristics
Variable SUP CTR P value
n = 18 n = 22
Age (year) 65.9 ± 9.7 68.3 ± 8.7 0.43
Male to female 12:6 17:5 0.50
DM to non-DM 4:14 9:13 0.31
ARB/ACEI (use to non-use) 17:1 18:4 0.36
Body weight (kg) 65.6 ± 6.6 66.0 ± 8.9 0.86
BMI (kg/m2) 25.0 ± 1.8 24.6 ± 2.9 0.66
%IBW 114 ± 8 112 ± 13 0.66
Energy (kcal/kg IBW/day) 29 ± 4 28 ± 5 0.49
Protein (g/kg IBW/day) 0.75 ± 0.18 0.78 ± 0.19 0.67
BUN (mg/dL) 37.0 ± 12.3 49.7 ± 21.6 0.03
Creatinine (mg/dL) 3.9 ± 2.0 4.6 ± 3.4 0.44
eGFR (mL/min/1.73 m2) 15.4 ± 7.1 13.6 ± 6.8 0.43
Indoxyl sulfate (log μg/mL) (μg/mL) 0.71 ± 0.49 (5.2) 0.82 ± 0.29 (6.3) 0.36
Urine protein excretion (g/day) 0.9 ± 0.9 2.3 ± 3.9 0.15
CRP (mg/dL) 0.04 ± 0.04 0.11 ± 0.15 0.10
Values inside parenthesis are the median
SUP supplement group, CTR control group (no supplement), DM diabetes mellitus, ARB angiotensin II receptor blocker, ACEI angiotensin-converting enzyme inhibi-
tor, BMI body mass index, IBW ideal body weight, BUN blood urea nitrogen, eGFR estimated glomerular filtration rate, CRP C-reactive protein
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Body weight and body composition are shown in
Table 2. Body weight, BMI, and %IBW were signifi-
cantly higher in the SUP group than in the CTR
group at 16 weeks. Body weight, BMI, and %IBW in
the SUP group increased significantly from baseline.
The intake of nutritional formula correlated with
change in body weight (r = 0.33, P < 0.05).Table 2 Nutrient intake, body weight, and body composition
SUP
Variable 0 week 8 weeks 1
Energy (kcal/kg IBW/day) 29 ± 4 30 ± 3
Protein (g/kg IBW/day) 0.76 ± 0.18 0.76 ± 0.20 0
Salt (g/day) 7.2 ± 2.3 7.3 ± 2.3
BW (kg) 65.6 ± 6.6 66.2 ± 6.4** 6
BMI (kg/m2) 25.0 ± 1.8 25.2 ± 1.9** 2
%IBW 114 ± 8 115 ± 9** 1
LBM (kg) 47.5 ± 7.4 – 4
BP (kg) 12.0 ± 1.9 – 1
ICW (kg) 21.6 ± 2.6 – 2
ECW (kg) 11.3 ± 1.7 – 1
Mineral (kg) 2.6 ± 0.3 –
BFM (kg) 17.1 ± 5.0 – 1
SUP supplement group, CTR control group (no supplement), Salt intake sodium chlo
BP body protein, LBM lean body mass, ICW intracellular water, ECW extracellular wa
*P < 0.05 versus CTR, **P < 0.05, ***P < 0.01 versus 0 weekLaboratory findings
Biochemical parameters and urine protein excretion are
shown in Table 3. Although BUN was significantly
higher in the SUP group than in the CTR group at
8 weeks, there were no significant differences between
two groups in all biochemical parameters and urine pro-
tein excretion at 16 weeks. There were no significant
changes from baseline to 16 weeks in both groups.CTR
6 weeks 0 week 8 weeks 16 weeks
30 ± 4 28 ± 5 29 ± 5 29 ± 5
.74 ± 0.19 0.78 ± 0.19 0.77 ± 0.26 0.78 ± 0.25
7.3 ± 2.1 8.2 ± 3.0 8.6 ± 3.8 7.7 ± 3.5
6.5 ± 6.5*, *** 66.0 ± 8.9 66.2 ± 8.6 65.7 ± 8.7
5.4 ± 2.0*, *** 24.6 ± 2.9 24.7 ± 2.9 24.3 ± 2.5
15 ± 9*, *** 112 ± 13 112 ± 13 110 ± 11
9.8 ± 10.5 48.9 ± 7.8 – 48.7 ± 7.6
2.6 ± 2.7 12.3 ± 2.0 – 12.3 ± 1.9
2.4 ± 4.2 21.8 ± 3.5 – 21.8 ± 3.5
2.1 ± 3.4 12.1 ± 2.2 – 12.0 ± 2.0
2.7 ± 0.5 2.7 ± 0.3 – 2.7 ± 0.3
5.7 ± 7.8 16.1 ± 5.2 – 15.9 ± 4.7
ride equivalent, BW body weight, BMI body mass index, IBW ideal body weight,
ter, BFM body fat mass
Table 3 Laboratory test
SUP CTR
Variable 0 week 8 weeks 16 weeks 0 week 8 weeks 16 weeks
Total protein (g/dL) 7.0 ± 0.4 6.9 ± 0.3 6.9 ± 0.4 6.8 ± 0.7 6.8 ± 0.7 6.9 ± 0.6
Albumin (g/dL) 4.1 ± 0.3 4.0 ± 0.3 4.1 ± 0.3 3.9 ± 0.6 3.9 ± 0.6 4.0 ± 0.4
Prealbumin (mg/dL) 32.8 ± 7.5 33.2 ± 7.7 33.2 ± 7.25 31.0 ± 6.6 30.5 ± 5.6 31.4 ± 6.4
Triglyceride (mg/dL) 143 ± 79 148 ± 93 158 ± 76 142 ± 98 147 ± 99 156 ± 89
T-Cho (mg/dL) 179 ± 36 177 ± 33 179 ± 32 173 ± 27 173 ± 29 173 ± 24
LDL-Cho (mg/dL) 95.4 ± 28.7 91.8 ± 24.8 94.7 ± 25.0 88.5 ± 18.7 89.6 ± 18.6 89.1 ± 22.9
HDL-Cho (mg/dL) 47.6 ± 17.6 46.6 ± 17.4 45.9 ± 16.2 46.9 ± 15.0 46.6 ± 15.7 45.4 ± 15.1
Creatinine (mg/dL) 3.9 ± 2.0 4.1 ± 2.5 4.1 ± 2.5 4.6 ± 3.4 5.0 ± 4.4 5.0 ± 4.2
BUN (mg/dL) 37.0 ± 12.3 39.5 ± 18.0* 38.5 ± 16.0 49.7 ± 21.6 47.5 ± 26.6 50.3 ± 16.4
CRP (mg/dL) 0.04 ± 0.04 0.06 ± 0.05 0.07 ± 0.08 0.11 ± 0.15 0.22 ± 0.61 0.06 ± 0.06
Ccr (mL/min) 22.7 ± 11.7 23.8 ± 12.1 21.9 ± 11.6 20.0 ± 10.7 21.1 ± 10.7 19.3 ± 9.9
UPE (g/day) 0.9 ± 0.9 1.0 ± 0.8 1.1 ± 1.2 2.3 ± 3.9 1.9 ± 3.9 1.5 ± 2.8
SUP supplement group, CTR control group (no supplement), T-Cho total cholesterol, LDL-Cho low-density lipoprotein cholesterol, HDL-Cho high-density lipoprotein
cholesterol, BUN blood urea nitrogen, CRP C-reactive protein, Ccr creatinine clearance, UPE urine protein excretion
*P < 0.05 versus CTR
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the significant difference was not observed in diabetic
patients (SUP: n = 4, 6.3 ± 0.2 to 6.2 ± 0.3, CTR: n = 9,
6.4 ± 0.9 to 5.9 ± 0.5, 0 to 16 weeks).
Plasma fatty acid composition
Plasma fatty acid composition is shown in Table 4.
Plasma EPA, α-linolenic acid, EPA/arachidonic acid
(AA) ratio, and n-3/n-6 ratio were significantly higher in
the SUP group than in the CTR group. In the SUP
group, EPA, EPA/AA ratio, and n-3/n-6 ratio increased
significantly from baseline. The intake of nutritional for-
mula correlated with change in EPA/AA ratio (r = 0.46,
P < 0.01). EPA and EPA/AA ratio were significantly
higher in the SUP group than in the CTR group. In theTable 4 Plasma fatty acid composition in all subjects (A) and in the
SUP
Variable 0 week 16
A. All subjects
EPA (μg/mL) 62.5 ± 37.0 8
DHA (μg/mL) 124.1 ± 63.8 14
ARA (μg/mL) 142.6 ± 45.5 14
α-Linolenic acid (μg/mL) 33.3 ± 17.2 3
n-3/n-6 ratio 0.24 ± 0.09 0
EPA/AA ratio 0.47 ± 0.34 0
B. Subgroup not prescribed EPA
EPA (μg/mL) 55.4 ± 34.4 7
EPA/AA ratio 0.36 ± 0.19 0
SUP supplement group, CTR control group (no supplement), EPA eicosapentaenoic a
eicosapentaenoic acid/arachidonic acid
*P < 0.05 versus CTR, ***P < 0.01 versus 0 weekSUP group, EPA and EPA/AA ratio increased signifi-
cantly from baseline.
In a subgroup analysis excluding participants receiv-
ing ethyl icosapentate (SUP group: n = 15, CTR group:
n = 16), EPA and EPA/AA ratio were significantly
higher in the SUP group than in the CTR group. In
the SUP group, EPA and EPA/AA increased signifi-
cantly from baseline.
Renal function and plasma indoxyl sulfate
Estimated GFR in the CTR group decreased significantly
by 1.2 ± 2.6 mL/min/1.73 m2 at 16 weeks, but eGFR in
the SUP group changed slightly by 0.1 ± 3.5 mL/min/
1.73 m2 and this change was not significant (Fig. 2a). In
addition, the changes of Ccr significantly correlated withsubgroup not prescribed EPA (B)
CTR
weeks 0 week 16 weeks
5.8 ± 50.0*, *** 87.7 ± 76.9 87.0 ± 77.2
9.9 ± 95.6 116.7 ± 52.9 118.4 ± 39.0
2.0 ± 47.3 150.7 ± 57.8 149.4 ± 44.0
9.0 ± 16.9* 31.6 ± 23.4 29.2 ± 12.9
.30 ± 0.11*, *** 0.28 ± 0.17 0.26 ± 0.12
.67 ± 0.51*, *** 0.72 ± 0.81 0.65 ± 0.62
5.6 ± 47.7*, *** 48.4 ± 27.3 43.7 ± 21.9
.51 ± 0.26*, *** 0.31 ± 0.19 0.31 ± 0.20
cid, DHA docosahexaenoic acid, ARA arachidonic acid, EPA/AA
Fig. 2 Effect of oral supplementation on eGFR (a) and plasma indoxyl sulfate (b). eGFR estimated glomerular filtration rate. Filled circles indicate
the SUP group. Open circles indicate the CTR group. †P < 0.05 versus 0 week
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showed a significant increase in plasma indoxyl sulfate
at 16 weeks, whereas the SUP group showed no signifi-
cant changes from baseline (Fig. 2b).
Discussion
In this study, we evaluated the effects of energy and nu-
trient supplementation using a high-calorie, low-protein
liquid formula containing various nutrients on patients
with CKD stage 4 and 5 before dialysis initiation.
The body weight in the SUP group was significantly
higher than that in the CTR group and significantly in-
creased from baseline. Moreover, the amount of intake
of the nutritional formula correlated with change in
body weight. Although energy intake was not signifi-
cantly changed, that in the SUP group tended to increase
from baseline (P = 0.07). This might mean that the nutri-
tional formula partially increased energy intake. Huang
et al. [14] reported that energy intake in over one half of
CKD patients was less than 90 % of the recommended
levels. In the present study, because all participants had
received dietary counselling from more than 1 month
before the study and had already taken various types of
low-protein foods and calorie supplements before this
study, the rate of energy intake for a prescribed amount
at baseline was higher than 90 %, and considered to be
relatively sufficient. For patients whose energy intake
was over the prescribed amount, they were advised dur-
ing dietary counselling to replace the part of their usual
foods with the nutritional formula to adjust energy in-
take to the prescribed level. Under such conditions, the
rate of energy intake in the SUP group increased from
93 to 98 % (P = 0.09). Therefore, using the nutritional
formula together with other low-protein foods may be
useful to improve the compliance to energy intake.
However, protein intake did not differ significantlybetween two groups. Moreover, protein intake did not
change from baseline in both groups and was similarly
maintained between 0.6 and 0.8 g/kg IBW/day. In
addition, it was considered that the formula had high re-
ceptivity and clinical adaptability because of its high
compliance. Taken together, the nutritional formula is
considered to be as useful as other low-protein foods for
protein control.
In addition, the formula provides various nutrients
that are supposed to be beneficial for CKD patients.
Among them, we focused on n-3 polyunsaturated fatty
acids (EPA, DHA) and prebiotics (lactulose, raffinose, in-
digestible dextrin). In the present study, we observed
significant increases in plasma EPA and EPA/AA ratio in
the SUP group. EPA and DHA are converted from α-
linolenic acid. However, due to the limited converting
activity, intake from diet is considered necessary. Al-
though EPA and DHA have various physiological effects,
there is insufficient evidence to set the dietary require-
ments for those effects. The minimum requirement of
EPA and DHA for healthy adults has been suggested to
be 250–500 mg based on the risk for cardiovascular
disease (CVD) [15]. Although EPA and DHA intake is
estimated to be higher in Japan than in many European
countries and the USA [16], inadequate intake accom-
panying a low-protein diet is a concern. The intake of
EPA and DHA during low-protein diet has been
reported to be 113 ± 153 mg and 156 ± 178 mg, respect-
ively [4]. In the present study, baseline EPA/AA ratio in
the subjects not prescribed EPA was low, because Yana-
gisawa et al. [17] reported that serum EPA/AA ratio of
healthy Japanese elderly (aged over 65 years) living in an
urban area was 0.68 ± 0.22. Therefore, supplementation
of the nutritional formula containing 130 mg of EPA
and DHA per pack may be useful for CKD patients on a
low-protein diet to prevent CVD events.
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but was not changed in the SUP group. Production of
indole, a precursor of indoxyl sulfate, by intestinal bac-
teria such as Escherichia coli is considered to alter
under various conditions [18, 19]. Lactulose and raffi-
nose are known to stimulate growth of Bifidobacteria in
the gut [20]. In addition, lactulose has been reported to
decrease fecal pH and indole [21]. In this study, protein
intake was not significantly different between SUP and
CTR groups. On the other hand, prebiotics including indi-
gestible dextrin in the SUP group presumably provide
carbohydrate as energy source to intestinal bacteria. Re-
garding dietary fiber, it is considered to be insufficient for
most people in general. In CKD patients, this trend may
be more prominent in the cases of lowering vegetable in-
take along with potassium control. Although it remains
unclear whether intestinal microflora, carbohydrate, pH,
or other factors were mainly involved in the increase in
plasma indoxyl sulfate in the CTR group, the lactulose,
raffinose, and indigestible dextrin contained in the nutri-
tional formula may be beneficial to maintain the intestinal
environment for CKD patients.
Estimated GFR declined in the CTR group, but was un-
changed in the SUP group. Whether supplementation of
nutrients by the present formula prevents the decline of
eGFR is of crucial interest. In this study, no significant dif-
ference in urinary protein excretion was observed. The in-
take of EPA and DHA was lower than that reported in the
meta-analysis [6]. However, the increase in plasma EPA/
AA ratio may have renoprotective effects. The decline of
renal function is known to induce compensatory hyperfil-
tration [22]. Prostaglandins have been associated with
renal hemodynamic regulation in response to protein
feeding [23]. Cyclooxygenase-2 inhibitor inhibits hyperfil-
tration by high protein intake in an animal model [24]. It
is possible that EPA competes with AA to influence eGFR
via cyclooxygenase-2. Another factor such as blood pres-
sure might be involved in renal function. EPA and DHA
are known to lower blood pressure [5]. However, it was
uncertain whether EPA and DHA were effective in high
blood pressure because most patients received antihyper-
tensive drugs including ARB/ACEI treatment under usual
therapy.
The increase in plasma indoxyl sulfate may affect eGFR
in the CTR group. Indoxyl sulfate is considered to be
nephrotoxic. A carbon adsorbent known to reduce serum
indoxyl sulfate prevented CKD progression in a small
study [25]. However, in the recent Evaluating Prevention
of Progression in CKD (EPPIC) study, the carbon adsorb-
ent was not effective in preventing CKD progression [26].
Further study is required to confirm whether indoxyl sul-
fate is related to kidney dysfunction and CKD progression.
Energy intake may also influence eGFR. Compared to
adequate or high energy intake, low energy intake wasrelated to decreased GFR [14]. In this study, whether
increase in the rate of energy intake in the SUP group,
improved eGFR remains unclear, because the rate of en-
ergy intake at baseline was already relatively high and
%IBW was greater than 100 % throughout the study.
The nutritional formula provides various nutrients. There-
fore, it is difficult to confirm a direct association between
the outcomes and each nutrient. Preservation of eGFR in
the SUP group is probably a complex effect of many nutri-
ents in this formula.
There are some limitations in this study. The number of
participants who could be evaluated for energy supple-
mentation by this formula was small, because many pa-
tients already had sufficient energy intake at screening.
The study period may also be insufficient to evaluate the
effect of the formula on eGFR. In the Modification of Diet
in Renal Disease (MDRD) study 2 with mean follow-up of
2.2 years, the participants had similar GFR to that in the
present study and the overall decline of GFR was 4.0 mL/
min/year [27]. The decline in eGFR in the CTR group (de-
cline of 1.2 mL/min/1.73 m2 during 16 weeks) was consid-
ered to be similar to that in MDRD study, whereas eGFR
in the SUP group hardly changed. The short study period
in the present study may account for no significant differ-
ence in eGFR detected between two groups. Much longer
studies are needed to ascertain whether energy and nutri-
ent supplementation is effective to prevent the decline of
eGFR and delay dialysis initiation.
Conclusions
The body weight, BMI, plasma EPA, and EPA/AA were
higher in the SUP group than in the CTR group. The de-
cline of eGFR and increase of plasma indoxyl sulfate from
baseline were not observed in the SUP group. High-
calorie, low-protein liquid formula containing EPA, DHA,
lactulose, raffinose, and indigestible dextrin was consid-
ered to be useful for nutritional management in patients
with chronic renal failure on protein-restricted diets.
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